Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from product quality group. The reporter is the patient.  A 74-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Oct2021 at 13:15 as dose 3 (booster), single (Lot number: FH8020) at the age of 73 years intramuscular, in left arm for covid-19 immunisation; coviD-19 vaccine janssen (COVID-19 VACCINE JANSSEN), on 07May2022 at 14:30 as dose 4 (booster), single (Lot number: 1855190), in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (COVID-19 VACCINE MODERNA), on 19Jan2021 at 18:00 as dose 1, single (Lot number: 013L20A), in left arm and on 16Feb2021 at 18:00 as dose 2, single (Lot number: 031L20A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hyperparathyroid" (unspecified if ongoing); "glaucoma" (unspecified if ongoing); "hypothyroid" (unspecified if ongoing); "Lyme disease" (unspecified if ongoing); "OA" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Timolol maleate gtts, reaction(s): "Known allergies: Timolol maleate gtts"; Levofloxacin, reaction(s): "Known allergies: Levofloxacin". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19; included Paxlovid from 05Jul2022 to 07Jul2022.  Conclusion of Previously Completed Investigation (FCI/SI/OffCI): The complaint for lack of effect of the PFIZER BIONTECH COVID-19 VACCINE INJECTABLE lot FH8020 was investigated. The investigation included reviewing manufacturing and packaging batch records, deviation investigations, analytical release test results, and an analysis of the complaint history for the reported lot. The final scope was determined to be the reported finished goods lot FH8020, fill lot FG3521, and the bulk formulated drug product lot FH0137. A complaint sample was not returned. No related quality issues were identified during the investigation. There is no impact on product quality. No root cause or CAPA were identified as the complaint was not confirmed. All release testing performed prior to the release of the reported batch was within specifications.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of the reported events cannot be totally excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.